Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea

RecruitingNot applicableNCT06757491

View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Objectives: To identify a central hub of visceral pain in IBS-D and elucidate the mechanism by which repetitive transcranial magnetic stimulation (rTMS) confers analgesic effects. Methods: A total of 42 IBS-D patients were recruited and randomly assigned (1:1) to the sham rTMS or the rTMS group. A nested cohort of 21 IBS-D participants who completed baseline fMRI assessments prior to randomization was included. Consistent with the randomization procedure，these individuals were evenly distributed between the two groups. Both participants and outcome assessors remained blinded to treatment allocation throughout the study. All patients completed the two-week intervention and were included in the final analysis.

Study details

Official title: Low-frequency Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea Via Inhibition of the Medial Prefrontal Cortex
Conditions: Repetitive Transcranial Magnetic Stimulation
Chronic Visceral Pain
Functional Magnetic Resonance Imaging
IBS (Irritable Bowel Syndrome)
Clinical Efficacy
Interventions: Device: Repetitive Transcranial Magnetic Stimulation
Device: Sham (No Treatment)
Sponsor: The First Affiliated Hospital of Soochow University
Start date: 2024-08-01
Primary completion: 2025-12-25
Sex: All
Age range: from 18 Years to 75 Years
Results posted: No results posted in this snapshot
Countries: China
Total sites listed: 1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)

All diagnoses were made by board-certified gastroenterologists. Eligible participants met the following inclusion criteria: (1) age between 18 and 75 years; (2) fulfillment of the Rome IV diagnostic criteria for IBS-D. Exclusion criteria included: (1) presence of inflammatory or other organic gastrointestinal diseases; (2) diagnosed psychiatric disorders; (3) history of anorectal, intestinal, or abdominal surgery; (4) pregnancy or lactation; (5) presence of metallic implants or cardiac pacemakers.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06757491